Net earnings per share (EPS TTM): Arcutis Biotherapeutics Inc (ARQT)

Graphic logo of Arcutis (ARQT)

Arcutis Biotherapeutics (ARQT) is aggressively scaling sales of non-steroidal treatments through US pharmacy chains. The current level of rolling earnings per share confirms this trajectory, with 0.22 representing the latest metric reading. A diverse range of drug formulations for dermatitis treatment minimizes regulatory threats, although ultimate success depends on insurance reimbursement and the results of future clinical trials.

ARQT Arcutis Corp Earnings per share for the last 12 months (07/04/2022 - 11/17/2026)

Analytical breakdowns for Arcutis Biotherapeutics Inc (ARQT)

- current quotes and average value forecast:
- company stock exchange capitalization indicators:
Initial company analysis:arcutis.com - ARQT
Mass-produced product of Arcutis

The efficiency of pharmaceutical logistics and temperature control compliance at Arcutis Biotherapeutics (ARQT) directly impact operating expenses, which determine the final net profit. This metric is calculated by dividing the total annual net income by the total number of shares, allowing investors to assess the asset's actual equity return via the per-share profit trend over the last 12 months.